USP 797 has minimum standards that are the framework of sterile compounding. However, many facets of sterile compounding are not covered in 797 or are left up to professional judgment. The applicability of the “Technology Statement” in USP 797, how to use official USP monographs, and the practical interpretation of “protect from light” information will increase the knowledge of sterile compounding personnel to achieve evidence-based, best-practice compounding practices.

Learning Objectives:

1. Explain the use of “alternative technologies, techniques, materials and procedures” statement in USP 797.

2. Summarize the availability and use of USP monographs for sterile compounding. Using an example of sterile-to sterile and API compounding, the participant will be able to identify the required tests in the USP monograph examples.

3. Identify the factors that contribute to the determination on when a CSP should be protected from light.

Speaker: George R. Smith, Pharm.D., BCPS, BCSCP, System Sterile Compounding Services Specialist, Prisma Health Department of Pharmacy

This free CE session is worth 1 contact hour.